Skip to main content

Corporate Governance

CME Group Names Jack Tobin CFO Ahead of March 2027 Leadership Transition

Chicago – September 15, 2026 -- CME Group has appointed Jack Tobin as its next Chief Financial Officer, effective March 2027, when current President & CFO Lynne Fitzpatrick becomes Chief Executive Officer.

Tobin moves to Deputy CFO in November 2026 ahead of formal handover

Tobin, CME Group's Chief Accounting Officer since 2015, will step into the Deputy Chief Financial Officer role in November 2026 to manage the transition before assuming the CFO title. He will continue reporting to Fitzpatrick and brings more than 35 years of financial experience, including accounting, corporate development and finance oversight at CME Group since joining in 2002. He previously worked as a principal consultant at PricewaterhouseCoopers and holds bachelor's and master's degrees from DePaul University.

ImmunoGenesis Adds Biopharma, Ex-USGA Chief to Board Ahead of 2027 Data

ImmunoGenesis Adds Biopharma, Ex-USGA Chief to Board Ahead of 2027 Data

Houston – September 15, 2026 -- ImmunoGenesis has appointed Reza Mazhari, Ph.D., and Mike Davis to its Board of Directors as the clinical-stage biotech advances its lead immunotherapy candidate toward key data readouts in mid-2027.

ImmunoGenesis has initiated a Phase 1b trial for lead asset IMGS-001

IMGS-001, a cytotoxic checkpoint inhibitor targeting PD-L1 and PD-L2, is being studied for immune-excluded tumors, a category that accounts for more than half of all cancers. James Barlow, President and CEO of ImmunoGenesis, said the new board members will help shape pipeline, partnering and fundraising strategy for the company's next growth phase.